Repligen (RGEN) is back in focus after its first quarter 2026 earnings, where profit topped market expectations, full year adjusted earnings guidance moved higher, and the stock gained 7.3% on the news.

Beyond the post earnings jump, Repligen’s 7 day share price return of 6.86% and 30 day share price return of 9.66% sit against a year to date share price decline of 23.07%. The 1 year total shareholder return of a 1.11% decline and 3 year total shareholder return of a 17.01% decline indicate that momentum has been rebuilding only recently around profit guidance, portfolio reshaping and the new China partnership.

If you are watching how the earnings story is changing sentiment around bioprocessing, it could be a good time to see what else is moving in healthcare focused AI, including the 35 healthcare AI stocks

With the stock still down for the year but trading at a reported 29% discount to one intrinsic value estimate and 42% below the average analyst target, is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 31.2% Undervalued

With Repligen last closing at $126.43 against a narrative fair value of $183.88, the current setup centers on how sustainably earnings and margins can build from here.

Strong and sustained order growth across biopharma, CDMO, and capital equipment segments, supported by record multi quarter book to bill ratios and a robust funnel, positions the company for above market revenue increases as therapy pipelines expand and demand for advanced bioprocessing solutions rises.

Want the full story behind that earnings ramp and margin lift, and how it feeds into a rich future P/E and cash flow outlook? The narrative walks through how revenue, profitability and valuation all connect over the coming years, and which assumptions really carry the fair value.

Result: Fair Value of $183.88 (UNDERVALUED)

However, investors still need to watch for softer funding at smaller biotech customers and any prolonged weakness in gene therapy or AAV demand, as this could unsettle this narrative.

Another Angle On Valuation

The earlier fair value of $183.88 paints Repligen as 31.2% undervalued, but its current P/E of 138.7x sits far above both the Global Life Sciences average of 37.1x and a fair ratio of 24.9x. This points to clear valuation risk if sentiment or growth expectations cool.

That gap suggests the market is already paying a heavy premium for future earnings. The key question is whether profit growth and execution can keep justifying such a rich multiple over time, or whether expectations eventually drift back toward the fair ratio.

Next Steps

Given that sentiment here is mixed, it helps to test the optimism in the numbers yourself and move quickly while the data is fresh. To see what the current optimism is based on, review the 4 key rewards.

Looking for more investment ideas?

If you stop here, you risk missing other opportunities that fit your style and risk level, so continue your research a little further.

• Target potential mispricing by scanning for quality companies trading below their perceived value with the 51 high quality undervalued stocks.
• Prioritise resilience by filtering for companies that pair stronger balance sheets with fundamentals that can better handle shocks using the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for underfollowed opportunities by running the screener containing 23 high quality undiscovered gems before the wider market starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.